ReviewPharmaceutics2021
Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 78 citations in OpenAlex.
- Targeted delivery of mRNA to immune cells forDrug delivery · 2026Review
- Advancements in RNA-based therapies from bench to bedside.npj drug discovery · 2026Review
- Lung-targeted RNA delivery systems: strategies and therapeutic applications.Journal of nanobiotechnology · 2026Review
- Antimicrobial peptides in the era of resistance: integrating AI-driven design, host-microbe interactions, and nanotechnological delivery.Frontiers in microbiology · 2026Review
- Messenger RNA therapy in bone and joint diseases: Rationale, delivery systems, and applications.Biomaterials translational · 2026Article
- mRNA based vaccines and therapeutics for parasitic infections: a comprehensive review.Journal of nanobiotechnology · 2025Review
- Comparative study on two kinds of brain-targeted liposomes co-modified by RVGP and R9 in different ways.International journal of pharmaceutics: X · 2025Article
- Delivery Systems of mRNA Vaccines in the Treatment of Infectious Diseases: From Lipid Nanoparticles to Next-Generation Platforms.Advanced pharmaceutical bulletin · 2025Review
- Recent Advances in mRNA Delivery Systems for Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights.Experimental hematology & oncology · 2025Review
- Research progress and strategy of FGF21 for skin wound healing.Frontiers in medicine · 2025Review
- Applications of mRNA Delivery in Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.Vaccine: X · 2024Review
- Review
- Peptosome: A New Efficient Transfection Tool as an Alternative to Liposome.International journal of molecular sciences · 2024Article
- From structural design to delivery: mRNA therapeutics for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Cyanophycin modifications for applications in tissue scaffolding.Applied microbiology and biotechnology · 2024Article
- 2D Materials Nanoarchitectonics for 3D Structures/Functions.Materials (Basel, Switzerland) · 2024Review
- mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles.International journal of molecular sciences · 2024Review
- Materials Nanoarchitectonics at Dynamic Interfaces: Structure Formation and Functional Manipulation.Materials (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Messenger RNAs (mRNAs) were previously shown to have great potential for preventive vaccination against infectious diseases and therapeutic applications in the treatment of cancers and genetic diseases. Delivery systems for mRNAs, including lipid- and polymer-based carriers, are being developed for improving mRNA bioavailability. Among these systems, cell-penetrating peptides (CPPs) of 4-40 amino acids have emerged as powerful tools for mRNA delivery, which were originally developed to deliver membrane-impermeable drugs, peptides, proteins, and nucleic acids to cells and tissues. Various functionalities can be integrated into CPPs by tuning the composition and sequence of natural and non-natural amino acids for mRNA delivery. With the employment of CPPs, improved endosomal escape efficiencies, selective targeting of dendritic cells (DCs), modulation of endosomal pathways for efficient antigen presentation by DCs, and effective mRNA delivery to the lungs by dry powder inhalation have been reported; additionally, they have been found to prolong protein expression by intracellular stabilization of mRNA. This review highlights the distinctive features of CPP-based mRNA delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.